Literature DB >> 2931449

Decreased autologous mixed lymphocyte reaction in multiple sclerosis.

D A Hafler, M Buchsbaum, H L Weiner.   

Abstract

The autologous mixed lymphocyte reaction (AMLR) measures the T-cell response to antigens on the surface of autologous non-T-cells. Studies have shown a decreased ability of T-cells to proliferate during the AMLR in a number of autoimmune and viral disorders. The AMLR was studied in 56 patients with multiple sclerosis (MS), a presumed autoimmune disease of the central nervous system, and the response was correlated with T-cell subsets. The AMLR was decreased in active MS patients (3 117 +/- 573 cpm) as compared to inactive patients (5 896 +/- 1 800 cpm) (P less than 0.05) and normal controls (7 782 +/- 1 725 cpm) (P less than 0.01). There was no significant difference between inactive patients and normal controls (P greater than 0.1). A more pronounced difference was also seen when patients with active disease associated with peripheral blood T4/T8 ratios greater than 3.0 (1 045 +/- 223 cpm) were compared with normal controls (P less than 0.01). In addition, MS patients with T4/T8 ratios of less than 1.0 had an increased AMLR (9 256 +/- 1 762 cmp) as compared to patients with either a high T4/T8 ratio (P less than 0.001) or normal ratio (P less than 0.05). Thus, multiple sclerosis patients with clinically active disease have a decreased AMLR which correlates with high T4/T8 ratios in a subgroup of patients.

Entities:  

Mesh:

Year:  1985        PMID: 2931449     DOI: 10.1016/s0165-5728(85)80034-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosis.

Authors:  G J Reclos; C N Baxevanis; C Sfagos; C Papageorgiou; G C Tsokos; M Papamichail
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

2.  Defective autologous mixed lymphocyte reactivity in multiple sclerosis.

Authors:  R L Hirsch
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

3.  Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis.

Authors:  R Benvenuto; M Paroli; C Buttinelli; A Franco; V Barnaba; C Fieschi; F Balsano
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

5.  Multiple sclerosis: I. Monocyte stimulatory defect in mixed lymphocyte reaction associated with clinical disease activity.

Authors:  C N Baxevanis; G J Reclos; C Sfagos; E Doufexis; C Papageorgiou; M Papamichail
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

6.  Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Authors:  Ivan Jelcic; Faiez Al Nimer; Jian Wang; Verena Lentsch; Raquel Planas; Ilijas Jelcic; Aleksandar Madjovski; Sabrina Ruhrmann; Wolfgang Faigle; Katrin Frauenknecht; Clemencia Pinilla; Radleigh Santos; Christian Hammer; Yaneth Ortiz; Lennart Opitz; Hans Grönlund; Gerhard Rogler; Onur Boyman; Richard Reynolds; Andreas Lutterotti; Mohsen Khademi; Tomas Olsson; Fredrik Piehl; Mireia Sospedra; Roland Martin
Journal:  Cell       Date:  2018-08-30       Impact factor: 41.582

Review 7.  Multiple sclerosis: possible immunological mechanisms.

Authors:  H F McFarland; S Dhib-Jalbut
Journal:  Clin Immunol Immunopathol       Date:  1989-01

Review 8.  Immunology of multiple sclerosis.

Authors:  H F McFarland
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.